Abstract 1435P
Background
SNF-CLIMEDIN aims to provide comprehensive care to advanced NSCLC patients through 3 pillars: clinical, molecular and digital. Molecular profiling is not yet reimbursed. In the era of new therapies remote support tools are needed.
Methods
In this prospective randomized non-interventional study in 200 NSCLC patients receiving standard 1st line therapy, 161 genes are analyzed via NGS. Clinicians report Adverse Events (AEs) in a study database; patients record AEs in a digital platform and are randomized to receive (investigational) or not (control) educational and supportive content. The impact of digital support on QoL is evaluated.
Results
This unplanned interim analysis studied 100 patients from 15 HeCOG centres. The Table shows clinical and molecular characteristics. The most common 1st line therapy was IO-chemo (80%). PR was 32%, SD 31%, 1-yr OS 64%, med PFS 5 months and med OS 8 months. Clinicians reported fatigue, haematological, liver and skin toxicities as the commonest gr3-4 AEs, while patients in the platform most often reported fatigue, cough, nausea, diarrhoea and anorexia. More AEs were reported in the platform than in the study database (89% vs 68% of patients, p<0.05). Platform use was higher in the investigational arm and rural areas. Patient-reported AE improvement was 78.4% (80.8% investigational vs 75.8% control). Most pts reporting AEs at least twice had ≥50% improvement. QoL and socio-demographic correlations with digital platform use will be presented. Table: 1435P
Clinical | Molecular | ||
Age median | 68 yrs | ||
Characteristic | % | Aberration | % |
Male | 80 | TP53 | 59 |
Smoker | 85 | KRAS | 27 |
Residence Urban | 85 | STK11 | 12 |
Live with Family | 82 | SMARCA4 | 10 |
Pensioners | 59 | EGFR | 6 |
>High school education | 73 | BRAF | 6 |
ECOG PS 0-1 | 97 | PIK3CA | 5 |
De Novo mets | 88 | PTEN | 5 |
Adenocarcinoma | 66 | BRCA1/2, ATM | 9 |
PDL-1 (+) | 56 | NOTCH | 9 |
MYC | 5 |
Conclusions
The study provides prospective evidence on NSCLC patients’ clinical and molecular profiles, treatment patterns and outcomes. Digital education and support led to increased AE reports and improvements, especially in the investigational arm. Socio-demographic factors influenced platform engagement, highlighting the significance of digital initiatives for patient-centered NSCLC care.
Clinical trial identification
NCT05372081.
Editorial acknowledgement
Legal entity responsible for the study
Hellenic Cooperative Oncology Group.
Funding
Stavros Niarchos Foundation donation.
Disclosure
H. Linardou: Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, MSD, Merck, Takeda, Bristol Myers Squibb, Lilly, Pfizer; Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, MSD, Bristol Myers Squibb, Pfizer, Amgen, Novartis; Financial Interests, Personal and Institutional, Local PI: Bristol Myers Squibb, Boehringer Ingelheim, Roche, AbbVie, Lilly, Novartis, AstraZeneca, Amgen, PPD, Parexel ILR, Qualitis, Health Data Specialist; Non-Financial Interests, Principal Investigator: Hellenic Cooperative Oncology Group; Non-Financial Interests, Leadership Role, Elected President of the Scientific Committee: Hellenic Cooperative Oncology Group; Non-Financial Interests, Member of Board of Directors: Women 4 Oncology - Hellas, Fairlife Lung Cancer Care. E. Fountzilas: Financial Interests, Personal, Other, travel grant: AstraZeneca, Genesis Pharma; Financial Interests, Personal, Invited Speaker: Roche, GSK, Amgen, Pfizer, AstraZeneca; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Stocks or ownership: Deciphera Pharmaceuticals, Inc. . A. Psyrri: Financial Interests, Personal, Invited Speaker: MSD, Merck Serono; Financial Interests, Personal, Advisory Board: Pfizer, Sanofi, MSD, AstraZeneca, BMS, Leo, Rakuten, eTheRNA immunotherapies, Merck Serono; Financial Interests, Personal and Institutional, Local PI: AstraZeneca, Pfizer, GSK, Genesis, MSD, Incyte, Amgen, Debiopharm, Janssen, Lilly, Regeneron, Sanofi, BI, Roche, Peregrine, Oncolytics Biotech; Financial Interests, Coordinating PI: AstraZeneca; Financial Interests, Personal and Institutional, Steering Committee Member: Iovance, Pfizer, Roche; Financial Interests, Institutional, Steering Committee Member: Kura Oncology; Financial Interests, Steering Committee Member: Kura Oncology; Financial Interests, Personal and Institutional, Funding: Kura Oncology, BMS, Roche, Demo, Amgen, BI, Genesis, BMS, Pfizer, Oncolytics Biotech; Financial Interests, Institutional, Funding: Merck Serono, Pfizer; Financial Interests, Personal, Other, Educational activity: Medscape, PrimeOncology; Financial Interests, Institutional, Local PI: Novartis, Replimmune; Non-Financial Interests, Project Lead, Medical Education with honoraria: Medscape. G. Mountzios: Financial Interests, Personal, Advisory Board: Roche, BMS, Takeda, Janssen; Financial Interests, Personal, Invited Speaker: MSD, AstraZeneca, Pfizer, Novartis, Amgen. J.I. Sgouros: Financial Interests, Personal, Advisory Board: Servier; Financial Interests, Institutional, Research Funding: Demo S.A., Innovis, Rafarm, WinMedica. G. Fountzilas: Financial Interests, Personal, Advisory Board: Pfizer, Novartis; Financial Interests, Personal, Other, Honoraria: AstraZeneca, Novartis; Financial Interests, Personal, Stocks/Shares: Genprex, Daiichi Sankyo , Formycon, RFL Holdings. P.A. Kosmidis: Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Other, Registration in Congress: Pfizer; Financial Interests, Personal, Other, Registration to Congress: Sanofi; Financial Interests, Personal, Ownership Interest: Careacross Digital Health Company. All other authors have declared no conflicts of interest.
Resources from the same session
1453P - Trends in treatment regimens and survival in the use of immune checkpoint inhibitors for lung cancer treatment in the Netherlands from 2016-2020
Presenter: Erick Suazo Zepeda
Session: Poster session 20
1454P - Radiomic analysis predicts response to immunotherapy in metastastic non-small cell lung cancer (mNSCLC): Preliminary results
Presenter: Salvatore Grisanti
Session: Poster session 20
1455P - Nivolumab (nivo) resumption in patients with advanced or metastatic non-small cell lung cancer (aNSCLC): Survival outcomes based on France and Germany real-world data (RWD)
Presenter: Maurice Pérol
Session: Poster session 20
1456P - Exploring biological and molecular factors as outcome predictors for pembrolizumab (Pem) or pembrolizumab-chemotherapy (Pem-CT) in advanced non-small cell lung cancer (NSCLC)
Presenter: Lodovica Zullo
Session: Poster session 20
1457P - Oligometastatic non-small cell lung cancer: Impact of local and systemic treatment approaches on clinical outcome
Presenter: Marcel Wiesweg
Session: Poster session 20
1459P - Preliminary efficacy and safety of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer who previously treated with immune checkpoint inhibitor(s)
Presenter: Caicun Zhou
Session: Poster session 20
1460P - GALLANT-1: GB1211 galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC)
Presenter: Francisco Aparisi Aparisi
Session: Poster session 20
1461P - Predictive value of residual FDG-PET metabolic activity in metastatic non-small cell lung cancer (mNSCLC) patients (pts) with long-lasting response to immune checkpoint inhibitors (ICIs)
Presenter: Toublanc Anne-Claire
Session: Poster session 20
1463P - IL-6 triggers chemoimmunotherapy resistance by creating immunosuppressive tumor microenvironment in non-small cell lung cancer
Presenter: Yaning Yang
Session: Poster session 20